4basebio Plc - Posting of Circular and Notice of General Meeting
News provided by
4basebio Plc20 Oct, 2026, 06:00 GMT
20 October 2026
4basebio PLC
(“4basebio” or the “Company”)
Posting of Circular and Notice of General Meeting
CAMBRIDGE, UK – 20 October 2026 - 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, is pleased to provide a further update in relation to the proposed Capital Raise announced on 15 October 2026.
The Company has today posted to shareholders a circular convening the General Meeting required in connection with the Capital Raise (the “Circular”), at which shareholders will be asked to consider, and if thought fit, approve, the Resolutions set out in the Circular. Completion of the Capital Raise is conditional on approval of the Resolutions.
The General Meeting will be held at 10.00 a.m. on 6 November 2026 at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4BQ. A copy of the Circular is also available to view on the Company’s website, www.4basebio.com/investors.
Please note that shareholders intending to attend the General Meeting in person will need a QR code, displayed on a smartphone or similar device, to access the meeting venue. A QR code can be obtained in advance by emailing info@4basebio.com with your full name, full address and email address, or on arrival for shareholders who have not done so in advance.
The Directors are of the opinion that the proposed Capital Raise is in the best interests of the Company and its shareholders as a whole, and unanimously recommend that shareholders vote in favour of the Resolutions, as they intend to do in respect of their own beneficial holdings.
Capitalised terms in this announcement shall have the same meaning as set out in the Circular.
Enquiries
4basebio PLC
+44 (0)12 2396 7943
Dr. Amy Walker – Chief Executive Officer
Richard Bungay – Chief Financial Officer
RBC Capital Markets (Global Co-ordinator, Joint Bookrunner and Joint Corporate Broker)
T: +44 (0)20 7653 4000
Kathryn Deegan – ECM
Max Avison – ECM Syndicate
Sandrine Cailleteau – Healthcare Advisory
Cavendish Capital Markets Limited (Joint Bookrunner and Joint Corporate Broker)
T: +44 (0)20 7220 0500
Geoff Nash, Andrea Callaghan – Corporate Finance
Nigel Birks – Healthcare Specialist Sales
Cairn Financial Advisers LLP (Nominated Adviser)
T: +44 (0)20 7213 0880
Jo Turner, Sandy Jamieson, Ed Downes
ICR Healthcare (Media and Investor Relations)
T: +44 (0)20 3707 5700
Jessica Hodgson / Ashley Tapp / Philip Marriage
About 4basebio
4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.
For more information, visit 4basebio.com .
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
